|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Protein C measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.
|
20802025 |
2010 |
|
Protein C antigen measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.
|
20802025 |
2010 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Using genetic models, we linked the PDE4-regulated modulation of P85 activation to the oncogenic kinase SYK.<b>Conclusions:</b> These data demonstrate that roflumilast and idelalisib suppress PI3K by distinct mechanisms, explaining the basis for their synergism, and suggest that the repurposing of PDE4 inhibitors to treat BCR-dependent malignancies is warranted.<i></i>.
|
29246942 |
2018 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma.
|
29782581 |
2018 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
CBFA2T2 expression is necessary for sphere-forming ability and cancer stem cells marker expression in RCC cell lines.
|
29162985 |
2017 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial.
|
28630349 |
2017 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In addition, the combination of P85 and (-)-gossypol effectively reduced clonogenic survival of A549 cells: (11 ± 5%) compared to (-)-gossypol and P85 alone (62 ± 27% and 93 ± 13%, respectively), and enhanced radiation cancer cell killing.
|
27827005 |
2017 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our study provides a proof of concept that blocking the interaction of p110α with p85 by a peptide can serve as a new strategy to inhibit the oncogenic activity of PI3K in cancer therapy.
|
28743532 |
2017 |
|
Malignant Neoplasms
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
|
23270540 |
2012 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
|
16131837 |
2005 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma.
|
29782581 |
2018 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our study provides a proof of concept that blocking the interaction of p110α with p85 by a peptide can serve as a new strategy to inhibit the oncogenic activity of PI3K in cancer therapy.
|
28743532 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition, the combination of P85 and (-)-gossypol effectively reduced clonogenic survival of A549 cells: (11 ± 5%) compared to (-)-gossypol and P85 alone (62 ± 27% and 93 ± 13%, respectively), and enhanced radiation cancer cell killing.
|
27827005 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial.
|
28630349 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
AlteredExpression
|
group |
BEFREE |
CBFA2T2 expression is necessary for sphere-forming ability and cancer stem cells marker expression in RCC cell lines.
|
29162985 |
2017 |
|
Primary malignant neoplasm
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
|
23270540 |
2012 |
|
Primary malignant neoplasm
|
0.080 |
Biomarker
|
group |
BEFREE |
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
|
16131837 |
2005 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth.
|
29588411 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In vivo, P85 (200 mg/kg/day) and (-)-gossypol (15 mg/kg/day) could be safely injected intravenously over 5 days and enhanced radiation-related tumor control in an A549 xenograft model.
|
27827005 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The short isoform p42 Ebp1, which is actual binding partner of ErbB3 has been implicated as a tumor suppressor with many binding partners such as Rb, HDAC2, Sin3A and the p85 subunit of PI3K with HSP70/CHIP, inhibiting its own antiproliferative activity or inhibiting PI3K activity.
|
27130196 |
2016 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
At low nM concentrations, EHT 6706 exhibits highly potent antiproliferative activity on more than 60 human tumor cell lines, even those described as being drug resistant.
|
22878926 |
2013 |